Slingshot members are tracking this event:
Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Mar 17, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Study, Axs-05, Treatment Resistant Depression, Stride-1, Trd, Major Depressive Disorder, Antidepressant, Bupropion